The Drug That Reverses Skin Aging & Speeds Healing

The core idea to understand first today is that of senolytics—compounds that destroy “zombie cells” while sparing healthy ones.

For a refresher on what “zombie cells” are, the medical term is “senescent cells“, but actually the popular term is a little more accurate in this case, because they are not merely cells that are getting old, but rather are also cells that failed to die when they were supposed to. These faulty cells accumulate with age, release inflammatory signals, get in the way of tissue repair, and slow down wound healing. Programmed cell death is an important part of how we function as organisms; it’s important to clear out the old cells to make way for the new ones.

Otherwise you just get undying (and yet increasingly faulty) cells building up and building up and if they keep at, then yes, this is absolutely connected to how cancer happens.

The relationship between cellular senescence and cancer is a bit more complicated than we have room to get into today, but if you’d like a bit more about senolytics in general before continuing, you might consider:

Fisetin: The Anti-Aging Assassin ← so-called because it works by killing the aging cells that need to die sooner rather than later if aging is not to be exacerbated by copying their mistakes forwards

A skin-deep approach

Normally, senolytic compounds are taken orally.

However, researchers (Dr. Maria Shvedova et al.) wondered if for rejuvenating skin, a topical approach could work better.

After all, not only is transdermal bioavailability often better than oral bioavailability (so long as the molecule size is small enough to penetrate the skin), but also, in this case, the skin is already where we want the action to be.

The general progress of science that led to this experiment was as follows:

1. Aging, senescence, and cutaneous wound healing—a complex relationship (2024)
2. Senescence as a molecular target in skin aging and disease (2025)
3. Senolytic-loaded asymmetric wound dressing for targeted senescent cell clearance in diabetic wound healing (2026)

…with that third one being the real “what if…” study that got the ball rolling with regard to a particular drug:

❝Using single-cell RNA sequencing, we characterized senescence-associated alterations in human diabetic foot ulcer tissues and screened several senolytic candidates in skin fibroblasts and endothelial cells. Among these, navitoclax (ABT-263) emerged as the most effective senolytic.

Incorporating ABT-263 into the fabric-based platform to prepare ABT-263-CGH, we confirmed its ability to reduce senescent cell burden while maintaining biocompatibility.

In a diabetic mouse model, the ABT-263-CGH significantly enhanced wound healing, reduced senescence markers, and exhibited no detectable systemic toxicity.❞

~ Dr. Ming Zhang et al.

Back to Dr. Maria Shvedova et al. hot on the heels of this a few months later, and the scope of the study was expanded, to look at reversal of aging and improvement of wound healing, without the “…in diabetes” element that may reduce its applicablility.

In few words, treated skin showed fewer markers of senescence after the topical treatment. Further, the treatment increased activity in genes involved in collagen production, blood vessel growth, tissue remodeling, and other repair processes. And in the case of testing its ability to hasten wound healing, in a mouse model, by day 24, it was found that 80% of treated mice had fully healed wounds, compared with 56% of untreated mice.

The closest thing to an adverse side effect was that ABT-263 caused a brief increase in inflammation, but this appeared to stimulate normal healing rather than cause harm, so in practical terms, even this was not an adversity, even if it probably felt adverse to the mice.

Aside from its obvious cosmetic applications, the main hope that Dr. Shvedova and her team have for this is that topical senolytic treatment could be used before surgery or in people at risk of poor wound healing to improve recovery.

We look forward to seeing it go to human trials, hopefully soon!

You can read the paper in full, here: Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing

Meanwhile, if you’d like a senolytic approach that’s a little more readily available than a drug approaching its early trial stages, then check out: The Drug & Supplement Combo That Reverses Aging

Want to learn more?

For a much deeper dive into the broader topic of cellular aging and rejuvenation, you might like this very good book that we reviewed:

How We Age: The Science of Longevity – by Dr. Coleen Murphy

Enjoy!